{"filings":[{"id":1729636,"accession_number":"0001493152-26-033829","cik":1873835,"company_name":"Immix Biopharma, Inc.","ticker":"IMMX","form_type":"8-K","filed_at":"2026-07-20T10:05:18+00:00","items":["8.01"],"status":"ready","headline":"Immix Biopharma terminates Richard Graydon; management sees no material impact","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Richard Graydon terminated effective July 17, 2026, for reasons unrelated to his company activities.","Management states Graydon's short tenure means no material effect on the business.","No replacement or further details on Graydon's role were disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":467394129.68041235,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":748878,"accession_number":"0001493152-26-026431","cik":1873835,"company_name":"Immix Biopharma, Inc.","ticker":"IMMX","form_type":"8-K","filed_at":"2026-05-29T21:10:15+00:00","items":["5.07"],"status":"ready","headline":"Immix Biopharma shareholders elect directors and ratify Crowe LLP as auditor at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All nine director nominees (including Ilya Rachman, Gabriel Morris, Jason Hsu) elected with over 35M votes each; broker non-votes ~6.4M.","Ratification of Crowe LLP as independent auditor for FY 2026 passed: 42.3M For, 11.5K Against, 18.4K Abstentions.","Meeting held May 22, 2026; results reported on May 29, 2026; overwhelming support for all proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":467394129.68041235,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":584517,"accession_number":"0001493152-26-024872","cik":1873835,"company_name":"Immix Biopharma, Inc.","ticker":"IMMX","form_type":"8-K","filed_at":"2026-05-21T21:28:23+00:00","items":["8.01","9.01"],"status":"ready","headline":"Immix Biopharma prices $150M public offering of 16.8M shares at $8.94","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds $150M; net proceeds ~$140.65M after discounts and expenses.","Offering of 16,778,524 shares priced at $8.94 per share; closes May 22, 2026.","Net proceeds to fund NXC-201 development, working capital, and general corporate purposes.","Cash runway extended to mid-2028 with existing cash plus offering net proceeds.","Morgan Stanley leads underwriters; BofA Securities, LifeSci Capital, Mizuho, Needham co-manage."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":467394129.68041235,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":563116,"accession_number":"0001493152-26-024707","cik":1873835,"company_name":"Immix Biopharma, Inc.","ticker":"IMMX","form_type":"8-K","filed_at":"2026-05-21T10:04:26+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Immix Biopharma reports 95% CR rate in NEXICART-2; all MRD-negative patients convert to CR","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All four MRD-negative relapsed/refractory AL Amyloidosis patients from ASH 2025 have converted to complete response (CR).","CR rate now 95% (19 of 20 patients) in Phase 2 NEXICART-2; no relapses observed in patients reaching CR.","All CRs reached within one year of follow-up post-dosing; median time to initial response was 7 days.","Phase 3 trial in newly diagnosed AL Amyloidosis planned to start in first half of 2027.","Next NEXICART-2 data update expected late September 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":467394129.68041235,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110364,"accession_number":"0001493152-26-013663","cik":1873835,"company_name":"Immix Biopharma, Inc.","ticker":"IMMX","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Immix Biopharma completes NEXICART-2 enrollment; topline results Q3 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enrollment complete for 40-patient BLA-enabling Phase 2 trial NEXICART-2 (NCT06097832) in relapsed/refractory AL Amyloidosis.","Topline results expected Q3 2026, followed by BLA submission and planned commercial launch for NXC-201.","Onboarded Chief Medical Officer Richard Graydon, MD, PhD, formerly of Merck and Johnson & Johnson.","NXC-201 has FDA Breakthrough Therapy, RMAT, and Orphan Drug Designations; market for AL Amyloidosis estimated at $6B in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":467394129.68041235,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110363,"accession_number":"0001493152-26-012721","cik":1873835,"company_name":"Immix Biopharma, Inc.","ticker":"IMMX","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Immix Biopharma ups ATM offering to $100M from $50M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Increased max aggregate offering price under ATM agreement from $50M to $100M.","Amendment updates registration statement to Form S-3 (File 333-292665).","Sales agent commission remains 3% of gross proceeds; $50K expense cap.","Company may sell shares at market prices from time to time; no minimum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":467394129.68041235,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126961,"accession_number":"0001493152-25-026697","cik":1873835,"company_name":"Immix Biopharma, Inc.","ticker":"IMMX","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Immix Biopharma raises ~$93.7M net via 19.1M share and warrant offering at $5.10","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["19,117,646 shares at $5.10/share and 490,196 pre-funded warrants at $5.09/warrant in underwritten offering.","Net proceeds expected ~$93.7M after underwriting discounts and estimated expenses.","Underwriting agreement with Morgan Stanley & Co. LLC as representative of underwriters.","Offering expected to close December 9, 2025, subject to customary closing conditions.","Pre-funded warrants exercisable immediately at $0.01/share, with 4.99% beneficial ownership limitation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":467394129.68041235,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126960,"accession_number":"0001493152-25-026500","cik":1873835,"company_name":"Immix Biopharma, Inc.","ticker":"IMMX","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Immix Biopharma reports 75% CR rate in Phase 2 NXC-201 for AL amyloidosis, BLA plan 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NXC-201 achieved 75% complete response (15/20) by independent review committee in relapsed/refractory AL amyloidosis.","MRD negativity in 4 of 5 pending patients suggests future CR rate could reach 95%.","Organ responses observed in 70% of evaluable patients; no neurotoxicity and only low-grade CRS (median 1 day).","NEXICART-2 final readout and BLA submission planned for 2026; therapy has FDA RMAT and orphan designations.","Current standard-of-care CR rate in this setting is under 10%, highlighting high unmet need."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":467394129.68041235,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126959,"accession_number":"0001493152-25-025182","cik":1873835,"company_name":"Immix Biopharma, Inc.","ticker":"IMMX","form_type":"8-K","filed_at":"2025-11-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Immix Biopharma files updated auditor consents for S-3 registration","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Filed updated consents from former auditor KMJ Corbin and current auditor Crowe LLP, dated Nov 26, 2025.","Consents relate to audit reports on FY2024 financials included in Form 10-K filed Mar 25, 2025.","Consents are for incorporation into Registration Statement on Form S-3 (No. 333-290725)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":467394129.68041235,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143759,"accession_number":"0001493152-25-012804","cik":1873835,"company_name":"Immix Biopharma, Inc.","ticker":"IMMX","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["1.01","3.02","5.02","9.01"],"status":"ready","headline":"Immix Biopharma raises $9.1M in PIPE; Nancy Chang appointed to board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 3,831,216 shares at $2.37/share and warrants for 2,873,417 shares at $2.00/share.","Gross proceeds ~$9.1M for working capital and general corporate purposes; closed on Sept 5, 2025.","Warrants are non-transferable, exercisable for 10 years, and only for cash.","Nancy Chang, Ph.D. appointed to board effective Sept 8, 2025; co-founded Tanox (XOLAIR developer).","Resale registration statement to be filed with SEC within 30 days of closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":467394129.68041235,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161993,"accession_number":"0001641172-25-016120","cik":1873835,"company_name":"Immix Biopharma, Inc.","ticker":"IMMX","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Immix Biopharma stockholders elect 8 directors and ratify Crowe LLP as 2025 auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 8 director nominees elected with 'for' votes ranging from 13.4M to 14.6M; broker non-votes 5.5M across all director proposals.","Ratification of Crowe LLP as independent auditor approved with 19.9M for, 47.6K against, 98.4K abstentions (no broker non-votes).","72.1% of outstanding shares (20.1M) were present or represented at the June 20, 2025 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":467394129.68041235,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161992,"accession_number":"0001641172-25-013417","cik":1873835,"company_name":"Immix Biopharma, Inc.","ticker":"IMMX","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Immix Biopharma enters ATM equity offering with Citizens JMP Securities","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement allows at-the-market sales of common stock; 3% commission to Agent.","Sales conducted under existing S-3 shelf (File No. 333-269100), filed January 2023.","No immediate sale; company controls timing, price, and size of any offerings.","Agent indemnified and reimbursed up to $50,000 for specified expenses.","Shares subject to registration limits and Nasdaq rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":467394129.68041235,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213143,"accession_number":"0001493152-24-029174","cik":1873835,"company_name":"Immix Biopharma, Inc.","ticker":"IMMX","form_type":"8-K","filed_at":"2024-07-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Immix Biopharma subsidiary Nexcella awarded $8M CIRM grant for NXC-201 AL Amyloidosis trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$8 million CLIN2 grant from California Institute for Regenerative Medicine to support NXC-201 CAR-T therapy for relapsed/refractory AL Amyloidosis.","NEXICART-2 U.S. Phase 1b/2 trial to evaluate NXC-201; builds on prior ex-U.S. data showing 92% overall response rate.","NXC-201 is the only CAR-T therapy in development for AL Amyloidosis and has Orphan Drug Designation from FDA and EMA.","No FDA approved drugs currently for relapsed/refractory AL Amyloidosis; CIRM grant adds non-dilutive funding to ongoing clinical program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":467394129.68041235,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213142,"accession_number":"0001493152-24-028595","cik":1873835,"company_name":"Immix Biopharma, Inc.","ticker":"IMMX","form_type":"8-K","filed_at":"2024-07-22T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Immix Biopharma replaces auditor KMJ Corbin with Crowe LLP after KMJ partners join Crowe","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Effective July 17, 2024, Immix dismissed KMJ Corbin & Company LLP and appointed Crowe LLP as its independent registered public accounting firm.","Change follows the partners and professional staff of KMJ joining Crowe; no disagreements or reportable events in fiscal 2022 or 2023.","KMJ's audit reports for the two most recent fiscal years were unqualified and contained no adverse or modified opinions.","KMJ provided a letter agreeing with the dismissal statements, filed as Exhibit 16.1 to this Form 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":467394129.68041235,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232260,"accession_number":"0001493152-24-023947","cik":1873835,"company_name":"Immix Biopharma, Inc.","ticker":"IMMX","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Immix Biopharma shareholders approve 3M-share increase and evergreen provision in equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved increasing omnibus equity plan shares by 3,000,000 to 4,934,561 total.","Evergreen provision adopted: automatic annual increase of 5% of outstanding shares on Jan 1 for 10 years from 2025.","All eight director nominees elected; ratification of KMJ Corbin & Company LLP as auditor passed.","Meeting had 70.4% of shares present, constituting a quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":467394129.68041235,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232259,"accession_number":"0001493152-24-020785","cik":1873835,"company_name":"Immix Biopharma, Inc.","ticker":"IMMX","form_type":"8-K","filed_at":"2024-05-20T23:59:59+00:00","items":["3.02","8.01","9.01"],"status":"ready","headline":"Immix Biopharma completes short-form merger of majority-owned subsidiary Nexcella","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["On May 20, 2024, Immix merged its >95%-owned subsidiary Nexcella into itself; Nexcella ceased to exist.","Issued 989,876 shares of common stock to former Nexcella stockholders (including third-party cash investors).","Issued 275,759 restricted stock awards and options to purchase 595,676 shares at $2.47 per share to former Nexcella equity plan participants.","Nexcella stockholders have appraisal rights under Delaware law if they perfect them."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":467394129.68041235,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250534,"accession_number":"0001493152-24-005043","cik":1873835,"company_name":"Immix Biopharma, Inc.","ticker":"IMMX","form_type":"8-K","filed_at":"2024-02-06T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Immix Biopharma prices $15M public offering of 5.5M shares at $2.71/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 5,535,055 shares at $2.71 per share; gross proceeds ~$15M before expenses.","Underwriter granted 30-day over-allotment option for up to 783,970 additional shares.","Net proceeds to fund NXC-201 clinical trials, working capital, and general corporate purposes.","Closing expected February 8, 2024; subject to customary conditions.","Directors and officers subject to 90-day lock-up expiring May 8, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":467394129.68041235,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250533,"accession_number":"0001493152-24-004933","cik":1873835,"company_name":"Immix Biopharma, Inc.","ticker":"IMMX","form_type":"8-K","filed_at":"2024-02-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Immix Biopharma suspends at-the-market equity offering under Sales Agreement with ThinkEquity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Suspended prospectus supplement dated July 14, 2023; no sales of common stock until new filing.","Sales Agreement with ThinkEquity LLC remains in full force and effect.","No reason given for suspension; company may resume after filing new supplement.","Suspension removes immediate dilution risk but pauses potential capital raising."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":467394129.68041235,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":285313,"accession_number":"0001493152-23-029822","cik":1873835,"company_name":"Immix Biopharma, Inc.","ticker":"IMMX","form_type":"8-K","filed_at":"2023-08-22T23:59:59+00:00","items":["1.01","3.02","5.02","9.01"],"status":"ready","headline":"Immix Biopharma raises $10M via private placement; appoints new director","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$10M from sale of 3.24M shares at $1.94/share and 1.91M pre-funded warrants at $1.9399.","Net proceeds of ~$9.55M; funds to be used for working capital and general corporate purposes.","Pre-funded warrants exercisable at $0.0001/share, no expiration, with 19.99% blocker provision.","Company to file resale registration statement within 30 days, seek effectiveness within 45 days.","Yekaterina Chudnovsky appointed to board as independent director effective August 22, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":467394129.68041235,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":285312,"accession_number":"0001493152-23-024626","cik":1873835,"company_name":"Immix Biopharma, Inc.","ticker":"IMMX","form_type":"8-K","filed_at":"2023-07-14T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Immix Biopharma enters ATM equity offering agreement with ThinkEquity LLC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATM Sales Agreement with ThinkEquity LLC allows at-the-market sales of common stock, subject to $75M public float limitation.","Commission rate of 3.75% of gross proceeds; company also reimburses legal fees up to $50,000 and quarterly fees.","Sales may occur on Nasdaq Capital Market or other trading markets at prevailing prices; agreement terminable on 10 days' notice.","Prospectus supplement filed July 14, 2023 under effective shelf registration statement (333-269100)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":467394129.68041235,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":305163,"accession_number":"0001493152-23-020507","cik":1873835,"company_name":"Immix Biopharma, Inc.","ticker":"IMMX","form_type":"8-K","filed_at":"2023-06-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Immix Biopharma shareholders elect 7 directors, ratify auditor, approve equity plan","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All seven director nominees elected: Rachman, Morris, Hsu, Marquet, Adams, Ng, Buchan.","Ratification of KMJ Corbin as auditor approved: 9,497,865 for, 36,813 against, 7,792 abstain.","Amended 2021 Omnibus Equity Incentive Plan approved: 7,315,768 for, 295,959 against, 10,792 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":467394129.68041235,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":324660,"accession_number":"0001493152-23-008484","cik":1873835,"company_name":"Immix Biopharma, Inc.","ticker":"IMMX","form_type":"8-K","filed_at":"2023-03-22T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Immix Biopharma enters ATM facility to sell up to $5M in common stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATM Sales Agreement with ThinkEquity LLC for up to $5,000,000 of common stock.","Shares sold at market prices; fixed commission of 3.75% of gross proceeds.","Offering made under existing S-3 shelf registration statement declared effective Jan 2023.","Expense deposit of $15,000 paid; legal fee reimbursement up to $50,000."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":467394129.68041235,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":324659,"accession_number":"0001493152-23-007312","cik":1873835,"company_name":"Immix Biopharma, Inc.","ticker":"IMMX","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["1.01","7.01"],"status":"ready","headline":"Immix Biopharma confirms no deposits at Silvergate or Silicon Valley Bank","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Neither Immix Biopharma nor its subsidiaries hold cash deposits or securities at Silvergate Bank or Silicon Valley Bank.","Disclosure addresses investor concerns following the recent bank failures.","No financial exposure to these institutions; company operations unaffected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":467394129.68041235,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":324657,"accession_number":"0001493152-23-007317","cik":1873835,"company_name":"Immix Biopharma, Inc.","ticker":"IMMX","form_type":"8-K/A","filed_at":"2023-03-13T23:59:59+00:00","items":["1.01","7.01"],"status":"ready","headline":"Immix Biopharma amends 8-K to clarify no deposits at Silvergate or Silicon Valley Bank","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filing corrects original 8-K's item number from 1.01 to 7.01 for Regulation FD disclosure.","Company confirms neither Immix nor its subsidiaries hold cash deposits or securities at Silvergate Bank or Silicon Valley Bank.","Disclosure addresses investor concerns during the March 2023 regional banking crisis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":467394129.68041235,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":324658,"accession_number":"0001493152-23-001795","cik":1873835,"company_name":"Immix Biopharma, Inc.","ticker":"IMMX","form_type":"8-K","filed_at":"2023-01-18T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Immix Biopharma subsidiary Nexcella raises ~$650k in private placement at $6.49/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nexcella entered share purchase agreements with accredited investors for 100,152 shares at $6.49/share.","Gross proceeds of approximately $650,000; after closing, Nexcella has 6,357,444 shares outstanding.","Offering exempt under Section 4(a)(2) and Rule 506 of Regulation D; shares are restricted securities.","Shares subject to drag-along rights and potential 365-day lock-up upon any future IPO of the subsidiary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":467394129.68041235,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":342489,"accession_number":"0001493152-22-035728","cik":1873835,"company_name":"Immix Biopharma, Inc.","ticker":"IMMX","form_type":"8-K","filed_at":"2022-12-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Immix Biopharma to use Nexcella slide presentation in investor meetings; no specifics given","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Slide presentation of wholly-owned subsidiary Nexcella to be used in third-party meetings.","No financial or operational details from the presentation are included in the filing.","Event is a routine FD disclosure; no substantive news provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":467394129.68041235,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":342488,"accession_number":"0001493152-22-035437","cik":1873835,"company_name":"Immix Biopharma, Inc.","ticker":"IMMX","form_type":"8-K","filed_at":"2022-12-14T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Immix Biopharma in-licenses NXC-201 CAR-T with 71% complete response in multiple myeloma","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["In-licensed exclusive worldwide rights (ex-Israel/Middle East) to NXC-201 (BCMA-targeted CAR-T) from Hadasit and BIRAD.","NXC-201 showed 85% ORR and 71% CR/sCR in 20 relapsed/refractory multiple myeloma patients; 100% ORR and organ response in AL amyloidosis.","Zero neurotoxicity observed; median CRS duration of 2 days at therapeutic dose, supporting potential outpatient use.","Financial terms: $1.5M upfront, $50k annual fee, mid-single digit royalties, up to $20M sales milestones.","Formed wholly-owned subsidiary Nexcella to develop NXC-201; expects minimal impact on Immix financials as Nexcella independently financed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":467394129.68041235,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":377998,"accession_number":"0001493152-22-016237","cik":1873835,"company_name":"Immix Biopharma, Inc.","ticker":"IMMX","form_type":"8-K","filed_at":"2022-06-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Immix Biopharma stockholders elect seven directors, ratify auditor at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All seven director nominees elected: Ilya Rachman, Gabriel Morris, Jason Hsu, Magda Marquet, Helen C. Adams, Carey Ng, Jane Buchan.","Ratification of KMJ Corbin & Company LLP as independent auditor approved with 9,023,287 for, 1,213,599 against, 11,599 abstain.","Total shares represented at meeting: 10,248,485, constituting a quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":467394129.68041235,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":396331,"accession_number":"0001493152-22-001557","cik":1873835,"company_name":"Immix Biopharma, Inc.","ticker":"IMMX","form_type":"8-K","filed_at":"2022-01-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Immix Biopharma announces positive interim safety data: 100% IMX-110 treatment cycle completion in Phase 1b/2a trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["100% of patients completed planned treatment cycles with IMX-110 without drug-related interruptions in ongoing Phase 1b/2a trial.","Historical comparators for approved soft tissue sarcoma drugs show 43-67% completion rates (Demetri et al., 2015; Schöffski et al., 2016).","IMX-110 has FDA Orphan Drug Designation for soft tissue sarcoma and Rare Pediatric Disease Designation for rhabdomyosarcoma.","Immix Biopharma (NASDAQ: IMMX) is developing IMX-110 as monotherapy for soft tissue sarcoma, a $3B market targeting $6.5B by 2030."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":467394129.68041235,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":396330,"accession_number":"0001493152-22-001044","cik":1873835,"company_name":"Immix Biopharma, Inc.","ticker":"IMMX","form_type":"8-K","filed_at":"2022-01-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Immix Biopharma reports IMX-110 50% response rate in STS mouse study, beating standard of care","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IMX-110 as monotherapy achieved 50% response rate in first-line-therapy-resistant STS mouse study, vs 0% for doxorubicin.","Study assessed by RECIST 1.1 criteria after one cycle; funded by Immix and conducted by major STS oncology center.","IMX-110 has FDA orphan drug designation for STS and rare pediatric disease designation for rhabdomyosarcoma.","Global STS market estimated $2.9B in 2019, projected to reach $6.5B by 2030.","Prior clinical data showed median PFS of 4 months with zero drug-related severe adverse events in heavily pretreated patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":467394129.68041235,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":396329,"accession_number":"0001493152-22-000069","cik":1873835,"company_name":"Immix Biopharma, Inc.","ticker":"IMMX","form_type":"8-K","filed_at":"2022-01-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Immix Biopharma gets FDA Rare Pediatric Disease designation for IMX-110 in rhabdomyosarcoma","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Rare Pediatric Disease designation for IMX-110 to treat rhabdomyosarcoma, a life-threatening pediatric cancer.","If approved, Immix may receive a Priority Review Voucher (PRV), historically sold for $67M to $350M, transferable to other companies.","IMX-110 is currently in a Phase 1b/2a clinical trial and also has orphan drug designation for soft tissue sarcoma.","Company believes IMX-110 targets all three components of the tumor micro-environment via its SMARxT platform."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":467394129.68041235,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":415379,"accession_number":"0001493152-21-032048","cik":1873835,"company_name":"Immix Biopharma, Inc.","ticker":"IMMX","form_type":"8-K","filed_at":"2021-12-20T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"Immix Biopharma closes IPO of 4.2M shares at $5.00/share for $21M gross proceeds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IPO closed Dec 20, 2021; shares began trading on Nasdaq Dec 16 under IMMX.","Gross proceeds $21M; underwriters have 45-day option for up to 630K additional shares.","Net proceeds to fund IMX-110 Phase 2a trial in soft tissue sarcoma and combination trial.","Also fund IND-enabling studies for IMX-111 (colorectal cancer) and IMX-120 (inflammatory bowel disease).","Filed amended charter and bylaws in connection with IPO closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":467394129.68041235,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}